Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Verition Fund Management LLC

Verition Fund Management LLC grew its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 340.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,115 shares of the biotechnology company’s stock after purchasing an additional 83,542 shares during the quarter. Verition Fund Management LLC owned approximately 0.07% of Heron Therapeutics worth $215,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of HRTX. Capstone Investment Advisors LLC acquired a new stake in Heron Therapeutics during the 3rd quarter valued at $45,000. Glenmede Trust Co. NA boosted its stake in shares of Heron Therapeutics by 49.6% during the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 10,578 shares during the last quarter. BNP Paribas Financial Markets increased its position in Heron Therapeutics by 50.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 275,946 shares of the biotechnology company’s stock worth $549,000 after purchasing an additional 92,425 shares in the last quarter. FMR LLC raised its stake in Heron Therapeutics by 26.2% in the 3rd quarter. FMR LLC now owns 431,906 shares of the biotechnology company’s stock valued at $859,000 after purchasing an additional 89,601 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Heron Therapeutics in the 3rd quarter valued at about $72,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on HRTX shares. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 11th.

Heron Therapeutics Price Performance

HRTX opened at $1.60 on Monday. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The business has a 50-day moving average of $1.58 and a two-hundred day moving average of $2.27. The stock has a market capitalization of $243.35 million, a price-to-earnings ratio of -8.89 and a beta of 1.67.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period last year, the company posted ($0.17) EPS. Equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.